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Summary
Designing improved vaccines against mutable viruses such as dengue and
influenza would be helped by a better understanding of how the B-cell
memory compartment responds to variant antigens. Towards this we have
recently shown, after secondary immunization of mice with a widely vari-
ant dengue virus envelope protein with only 63% amino acid identity,
that IgM+ memory B cells with few mutations supported an efficient sec-
ondary germinal centre (GC) and serum response, superior to a primary
response to the same protein. Here, further investigation of memory
responses to variant proteins, using more closely related influenza virus
haemagglutinins (HA) that were 82% identical, produced a variant-
induced boost response in the GC dominated by highly mutated B cells
that failed, not efficiently improving serum avidity even in the presence of
extra adjuvant, and that was worse than a primary response. This sup-
ports a hypothesis that over a certain level of antigenic differences, cross-
reactive memory B-cell populations have reduced competency for affinity
maturation. Combined with our previous observations, these findings also
provide new parameters of success and failure in antibody memory
responses.
Keywords: affinity maturation; antibodies; B-cell memory; cross-reactive;
influenza virus.
Introduction
Foreign antigens stimulate the formation of memory B
cells that have undergone somatic hypermutation
(SHM) of their antibody genes and selection in germinal
centres (GCs).1,2 In this manner, immunity is estab-
lished against identical pathogens. Despite the impor-
tance of understanding protection against mutable
viruses such as dengue and influenza viruses, however,
how memory B cells respond to variant antigens is
poorly understood.
We have recently shown that antibody memory
responses to widely variant proteins involved secondary
GCs with a higher proportion of IgM+ B cells, with fewer
VH mutations,1 compared with the memory response to
the homotypic antigen. These observations support the
idea that ‘lower’ layers of the B-cell memory compartment,
with less SHM, could furnish secondary responses against
variant antigens.3–5
A complication of sequential infection by certain vari-
ant viruses, however, is that immune responses to the sec-
ond virus can be compromised. In such situations,
termed antigenic sin, cross-reactive memory-derived anti-
bodies are induced that have a lower avidity and may
increase pathology, as they are non-neutralizing or
enhance infectivity.6–9 A critical question is why such
memory responses then fail to rapidly evolve higher affin-
ity to variant antigens through a secondary GC reaction.
Using sequential immunization with variant influenza
virus haemagglutinins (HA), which we have selected
because they are more closely related than the previ-
ously used dengue virus proteins, we have identified an
antibody memory response to a variant antigen that
exhibits inefficient secondary affinity maturation
Abbreviations: Bris, Brisbane 59/07; ELISA, enzyme-linked immunosorbent assay; GC, germinal centre; HA, haemagglutinin; RT-
PCR, reverse transcription–polymerase chain reaction; SHM, somatic hypermutation
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associated with altered GC reactions and mutation pro-
files, linking ‘antigenic sin’ to altered GC activity for
the first time.
Materials and methods
Mice, immunization, antigens
All antigens were from Sino Biologicals (Beijing, China)
and female 8- to 11-week-old BALB/c mice were obtained
from Charles River Laboratories (Margate, UK). Most
primary immunizations were, 25 lg PR8/34 HA1 alum
precipitated with 2 9 107 heat-killed Bordetella pertussis
administered intraperitoneally. Brisbane 59/07 (Bris) HA1
or HA was also used for priming as stated in the Results
section, also with alum/pertussis. Secondary immuniza-
tions were 25 lg PR8/34 or Bris HA protein administered
intraperitoneally in phosphate-buffered saline, or with
Sigma Adjuvant System (Sigma-Aldrich, Gillingham, Dor-
set, UK), as stated in the Results section. Rationale for
HA1 priming/HA boost was to focus the response away
from the conserved stem and on to the variable epitopes
of the head and to avoid sequential exposure to the C-
terminal HA1/His tag region, to reduce confounding
sequence similarities. All animal experiments were per-
formed under UK Home Office license PPL 30/3089 with
permission from the University of Exeter local animal
welfare ethics review board.
ELISA
Standard protocol for enzyme-linked immunosorbent
assay (ELISA) used 1 lg/ml coating protein in bicarbon-
ate buffer. End-point titre values plotted are log2 of
1/(end-point dilution 9 100), each unit increase repre-
sents a doubling of titre.
Urea avidity ELISA
Standard ELISA was performed, following Puschnik
et al.,10 then after the serum step, we performed 19
wash, 10-min incubation with 7 M urea/Phosphate-buf-
fered saline Tween (PBST), 29 wash, then standard pro-
tocol. Avidity index was calculated as 7-M urea readings/
readings from PBST-only treatment, after subtraction of
background.
Flow cytometry
Red blood cell-depleted spleen cells were incubated with
Fc-block (BD Biosciences, Wokingham, Berkshire, UK)
then allophycocyanin-conjugated anti-B220, BV421-conju-
gated anti-CD38 and phycoerythrin-conjugated anti-
CD95/Fas (BD), and anti-IgM (eBioscience/Thermo-Fisher
Scientific, Paisley, UK), following standard protocols.
B-cell antibody sequencing
Single GC B cells were sorted into 10 ll chilled 10 mM
Tris–HCl pH 80, 1 U/ll RNAsin (Promega, Southamp-
ton, UK) and frozen at 80°. One-Step reverse transcrip-
tion–polymerase chain reaction (RT-PCR) (Qiagen,
Manchester, UK) was performed with primer sets as
described by Tiller et al.11, for 50 cycles annealing at 536°.
Heavy-chain second-round PCRs used 2 ll first-round
PCR, Tiller et al.11 primers, and Taq (Qiagen) for 50 cycles
with annealing at 56°. Products were sequenced using pri-
mer 5ʹ-MsVHE,11 which leaves part of the 5ʹ end of FR1
unsequenced; hence, FR1 was not analysed. VH sequences
were analysed using IMGT V-QUEST platform. Sequences
are given in the Supplementary material (Table S1).
Statistics
Three mice were randomly allocated to cages. For greater
sample sizes, treatments were independently replicated.
Where t-test was applied, data points were analysed for
equality of variance; where this was violated they were
subject to a two-tailed test for unequal variance, other-
wise a two-tailed test for equal variance was used.
Results
Primary and secondary responses to PR8 HA
We defined the serum and GC response after a homo-
typic antigen prime-boost. Mice were primed with PR8/
34 (PR8) HA1 with adjuvant and boosted 38 days later
with soluble PR8 HA (see Materials and methods for
explanation).
Priming induced an increasing IgG titre to day 44
(Fig. 1a). Boosting increased the titre modestly (twofold)
but significantly by day 17. Levels of GC B cells rose from
a background of 018% to 075% by day 6 after priming,
remained elevated until day 17, and fell to background by
day 44 (Fig. 1b,c). Boosting induced GC B cells to a sig-
nificantly higher level, 15%, by day 6, which reduced by
day 17, but not significantly (Fig. 1c).
VH mutations increased by day 17 after priming, con-
sistent with active SHM and affinity maturation (Fig. 1d).
Boosting induced GC B cells with a higher level of VH
mutation at day 6 (median = 3) than seen at day 6 after
priming (median = 15), consistent with a response from
memory B cells focused on the HA1 head region. GC B
cells then accumulated further mutations by day 17 after
boost (median = 6), consistent with further affinity matu-
ration. Analysis of the relative avidity of serum IgG
(Fig. 1e) showed a rapid increase by day 6 after PR8 HA
boosting, which points to stimulation of the highest affin-
ity memory cells by the homotypic boost. There was a
further increase by day 30, up to 51%.
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A failed secondary response to heterotypic HA
After PR8 HA1 priming, we performed boosts with Bris
HA, which has 82% identity with PR8 over the HA1 region.
Initially, the boosts were not adjuvanted because this was
not previously necessary to induce successful heterotypic
secondary responses.1 In the experiments reported below,
however, because of the poor durability of the non-adju-
vanted boost response in the GC, we repeated all boosts
with an adjuvant. In this way, we sought also to determine
if adjuvant increased the longevity of the GC response, and
if it did, what effect this had on the resulting affinity matu-
ration. Figure 2(a) shows the serum titres induced by the
heterotypic Bris HA boosts, a Bris HA prime and a Bris/
Bris prime-boost.
Without adjuvant, the heterotypic Bris HA boost
induced a robust GC response by day 6, up to just over
10%, which collapsed by day 17 to 03%, close to the
pre-boost background level of 018% (Fig. 2b). This con-
trasted with the sustained response seen after PR8 HA
boosting, and the responses after boosting with heteroty-
pic dengue virus proteins, which were still fourfold to
eightfold above background at day 17.1 Analysis of total
VH mutations in Bris HA boosted GC B cells showed the
same profile as the PR8 HA boost (Fig. 2c). With the
previously reported heterotypic dengue virus proteins,
early GC B cells had fewer mutations, compared with the
homotypic boost.1 Further, here, at day 6 after Bris HA
boosting, there was a lower proportion of IgM+ B cells
(Fig. 2d) compared with the homotypic PR8 boost, again
contrasting with the dengue virus protein responses.
There was not a significant increase in the relative avidity
of serum IgG detected by day 30 after Bris HA boost, to
32% (Fig. 2e). This rise was less than that seen after a
Bris HA prime, up to 51% at day 30 (Fig. 2e), and het-
erotypic dengue-4 envelope-protein boosting, up to 53%
by day 32.1
To test whether Bris HA is not just a weaker antigen,
we performed a homotypic Bris/Bris prime-boost. This
induced similar levels of early GC B cells (12%; Fig. 2b)
to the homotypic PR8 prime-boost (15%; Figs 1c and
2b), which then declined slightly by day 17, to 07%. It
also indeced twofold higher serum IgG titres (Fig. 2a)
compared with the homotypic PR8 prime-boost (Fig. 1a),
suggesting that its antigenicity is similar.
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Figure 1. Primary and secondary response to homotypic PR8 haemagglutinin (HA). (a) Anti-PR8 HA serum IgG response. Bar shows mean. Px,
x days since priming; Bx, x days since boosting; BO, adjuvant-only primed, PR8 HA boosted, analysed day 6; His, B6 serum sample reactivity
with irrelevant C-terminal His-tagged protein (Bacillus clausii pdxR). (b) FACs gating strategy. (c) GC B-cell response to PR8 HA. Bar shows
mean. NI, not immunized; other labels as for panel (a). (d) VH mutations in single sorted germinal centre (GC) B cells. From n = 3 mice (Px)
and n = 6 mice (Bx). Bar shows median value. Labels as for panel (a). (e) Relative serum IgG avidity for PR8 HA. Bar shows mean. Labels as for
panel (a).
ª 2019 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology 3
Mutated memory B cells in an inefficient secondary response
Effect of adjuvant on the heterotypic Bris HA boost
response
Adjuvants containing Toll-like receptor ligands can
increase GC responses.12
Adjuvanted Bris HA boosts induced a nearly fourfold
increase in IgG titre at day 17, above that of the non-
adjuvant boost (Fig. 2a), and induced sustained GC B-
cell levels, rising to 12% of lymphocytes by day 6 and
only falling to 09% by day 17 (Fig. 2b). At day 30,
however, the IgG titre was similar in adjuvanted Bris
HA-boosted mice compared with Bris HA-primed mice
(Fig. 2a).
Early GC B cells had similar, if not greater, levels of
VH mutation (median = 4) compared with the non-adju-
vanted boost (median = 3; Fig. 2c), and an equivalent
proportion of IgM GC B cells (Fig. 2d), implying that no
extra naive cells were recruited to GCs by adjuvant. By
day 17, median VH mutations in this group had only
increased by one (Fig. 2c).
The adjuvanted Bris HA boost induced a significant
increase in serum avidity from day 6 to day 30, but only
to levels comparable to those seen with the Bris HA
prime group, being 54% versus 51%, and not approach-
ing the avidity of the homotypic Bris HA1/Bris HA
prime-boost which was 72% (Fig. 2e). Considering the
net level of increase in avidity between day 6 and day 30,
the Bris HA prime was more efficient (41% increase)
than the adjuvanted heterotypic boost (28% increase).
Altered selection of VH mutations in Bris HA-
boosted mice
Despite a sustained GC reaction, the adjuvanted Bris HA
response only supported a slight increase in overall VH
mutation (median = +1) between days 6 and 17 (Fig. 2c),
compared with the PR8 HA1 primary (+25), PR8 HA
boost (+3) and dengue-4 envelope protein boost (+4).1
Analysis of the levels of VH mutations in IgM and IgG
showed further evidence of altered selection. The primary
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Figure 2. Secondary responses to variant
haemagglutinin (HA) boosting. (a) Anti-Bris-
bane 59/07 (Bris) HA serum IgG titres after
Bris HA boosting. Bars indicate mean. x-axis
labels: P44, PR8 HA1 prime only, day 44. All
other labels: Px, x days since priming with
antigen indicated below; Bx, x days since
boosting with antigen indicated below. Bris,
Bris HA, Bris + A, Bris HA including adjuvant.
Note: The Bris* prime was performed with
Bris HA, not HA1, to allow appropriate com-
parison with Bris HA-boosted groups. (b) Ger-
minal centre (GC) B-cell response to Bris HA
boost. Bars show mean. First three data sets
reproduced from Fig. 1(c) for comparison.
x-axis labels as for panel (a). (c) VH mutations
in single sorted GC B cells. From n = mice in
each group indicated. Bar shows median.
x-axis labels as for panel (a). First two data sets
reproduced from Fig. 1(d) for comparison. (d)
Proportion of IgM+ GC B-cells in day 6 GC.
Bar shows mean. x-axis labels as for panel (a).
(e) Relative serum IgG avidity for Bris HA.
Bars show mean. x-axis labels as for panel (a).
(f) VH mutations in IgM+ and IgG+ GC B
cells. Number of mice in each group indicated
as n = . Bars indicate median. x-axis labels as
for panel (a).
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and secondary responses to PR8 HA and the heterotypic
dengue protein E4 and E2 responses all showed increases
in IgM VH mutation of between +15 and +45 as the GC
response matured (Fig. 2f, and ref. 1). In the adjuvanted
Bris HA boost response, there was no increase in IgM
mutations. The non-adjuvanted Bris HA boost response
was not included in this analysis as the failure of the GC
reaction implies that few cells were successfully selected
to day 17.
Discussion
We have shown how B-cell memory responses to boost-
ing with heterotypic antigens can be inefficient. With the
non-adjuvanted heterotypic Bris HA boosts, GC B-cell
numbers collapsed by day 17 despite ongoing SHM, and
serum avidity failed to increase significantly, contrasting
with heterotypic dengue protein boosts in mice, and
reproducing an ‘antigenic sin’ response. With adjuvant,
Bris HA boosting induced comparable IgG titres but a
smaller increase in serum avidity than the primary
response to Bris HA. Considering the adjuvanted Bris HA
boost response initiated with 36-fold higher numbers of
GC B cells (day 6) above background (Fig. 2b), it is less
efficient than the primary response. The presence of a
cross-reactive memory B-cell compartment, therefore, was
an impediment to the response to Bris HA.
We do not consider that the failed secondary response
to the non-adjuvanted heterotypic Bris HA boost could
be due to blocking by pre-existing cross-reactive antibod-
ies because this effect would be stronger in the homotypic
boosts (PR8/PR8 and Bris/Bris), which both show longev-
ity of the GC reaction.
We previously reported that successful heterotypic sec-
ondary responses had early GCs containing more IgM+ B
cells with fewer mutations.1 The heterotypic responses to
Bris HA reported here had early GCs with lower propor-
tions of IgM+ B cells (Fig. 2d), with equivalent or even
higher levels of mutation compared with the homotypic
boost (Fig. 2c). In the adjuvanted Bris HA boost, the high
levels of mutation in IgM failed to increase further by
day 17 (Fig. 2f). We propose that these heterotypic sec-
ondary responses to Bris HA were compromised because
the antibody’s ability to evolve was reduced. This could
be due to an intrinsic loss of ability to evolve in mutated
V genes, as they have lost hotspots for the aicd mutator,
lost codons predisposed to non-conservative substitu-
tions13 and despite being diverse at the sequence level
may be more restricted in V-gene diversity. It could also
be for GC dynamic reasons, such as increased SHM and
class switching affecting GC B-cell longevity and fate.14
The model of Deem and Lee15 provides a mathematical
description of this. It predicts that over a certain window
of antigenic difference, highly mutated memory responses
to variant antigens can be worse than primary responses,
despite memory B cells initiating with a higher affinity
than naive cells, which also explains their dominance of
the recall response.
It seems that the HA1 region of the Bris HA protein
was sufficiently similar to PR8 HA1 (82% identity) to
recruit the most mutated, and more often class-switched,
anti-PR8 HA1 memory cells, which were then inefficient
at further improving affinity for Bris HA. This outcome
contrasts with the efficient affinity maturation previously
observed with less mutated memory B cells1 and indicates
that mutation levels are an important parameter for
assessing the eventual success of cross-reactive vaccine
protection. We consider that the effects reported here are
relevant to understanding sub-optimal immune responses
against pandemic strains of influenza where antigenic dif-
ferences are larger compared with seasonal influenza epi-
demics, which are usually associated with a few mutations
in the HA protein.
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